NCT02362997 2026-02-12
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
8 trialsNCT02362035 2025-12-11
KEYNOTE145
Acerta Pharma BV
Phase 1/2 Completed
NCT04875195 2025-10-29
MK-3475-B68
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03331341 2025-08-05
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Phase 1/2 Completed
NCT02453594 2024-10-29
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03077828 2023-06-02
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT03776864 2023-05-03
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
University of Washington
Phase 2 Terminated
NCT01953692 2021-08-04
MK-3475-013
Merck Sharp & Dohme LLC
Phase 1 Completed